JP2011506400A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506400A5
JP2011506400A5 JP2010537456A JP2010537456A JP2011506400A5 JP 2011506400 A5 JP2011506400 A5 JP 2011506400A5 JP 2010537456 A JP2010537456 A JP 2010537456A JP 2010537456 A JP2010537456 A JP 2010537456A JP 2011506400 A5 JP2011506400 A5 JP 2011506400A5
Authority
JP
Japan
Prior art keywords
drug substance
suspension
solvent
drug
high pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010537456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/067364 external-priority patent/WO2009074666A1/en
Publication of JP2011506400A publication Critical patent/JP2011506400A/ja
Publication of JP2011506400A5 publication Critical patent/JP2011506400A5/ja
Pending legal-status Critical Current

Links

JP2010537456A 2007-12-13 2008-12-11 有機化合物 Pending JP2011506400A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123165 2007-12-13
PCT/EP2008/067364 WO2009074666A1 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (2)

Publication Number Publication Date
JP2011506400A JP2011506400A (ja) 2011-03-03
JP2011506400A5 true JP2011506400A5 (cg-RX-API-DMAC7.html) 2012-02-16

Family

ID=39387173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537456A Pending JP2011506400A (ja) 2007-12-13 2008-12-11 有機化合物

Country Status (13)

Country Link
US (1) US20100266696A1 (cg-RX-API-DMAC7.html)
EP (1) EP2229148B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011506400A (cg-RX-API-DMAC7.html)
KR (1) KR20100095587A (cg-RX-API-DMAC7.html)
CN (1) CN101896165B (cg-RX-API-DMAC7.html)
AU (1) AU2008334547B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820745A2 (cg-RX-API-DMAC7.html)
CA (1) CA2707594C (cg-RX-API-DMAC7.html)
ES (1) ES2460576T3 (cg-RX-API-DMAC7.html)
PL (1) PL2229148T3 (cg-RX-API-DMAC7.html)
PT (1) PT2229148E (cg-RX-API-DMAC7.html)
RU (1) RU2496479C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009074666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
CN103501791B (zh) * 2011-05-03 2016-05-18 奇斯药制品公司 用于通过吸入给药的改良皮质类固醇悬浮制剂
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT107433B (pt) * 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
CN106749008A (zh) * 2015-11-23 2017-05-31 北京九和药业有限公司 一种马来酸茚达特罗的微粉化方法及其应用
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
US20240293317A1 (en) * 2020-04-20 2024-09-05 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CA2559915C (en) * 2004-03-23 2013-07-02 Novartis Ag Micronization of pharmaceutically active agents
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
CN101102740A (zh) * 2005-01-07 2008-01-09 卫材R&D管理有限公司 药用组合物以及其制备方法
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
RU2008108176A (ru) * 2005-08-26 2009-10-10 Астразенека Аб (Se) Комбинация соединений, которая может быть применена в лечении респеративных заболеваний, особенно хронического обструктивного заболевания легких (copd) и астмы
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations

Similar Documents

Publication Publication Date Title
Singh et al. Enhancing solubility of poorly aqueous soluble drugs: Critical appraisal of techniques
Salústio et al. The influence of the preparation methods on the inclusion of model drugs in a β-cyclodextrin cavity
Raimi-Abraham et al. Development and characterization of amorphous nanofiber drug dispersions prepared using pressurized gyration
WO2014161131A1 (en) PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
CN102228430A (zh) 水飞蓟宾磷脂复合物的纳米混悬剂及其制备方法
JP6845915B2 (ja) 注射のためのテコビリマットの医薬組成物およびその調製方法
JP2010526848A (ja) 難溶性薬物用の医薬組成物
Pas et al. Preparation of amorphous solid dispersions by cryomilling: chemical and physical concerns related to active pharmaceutical ingredients and carriers
US11318115B2 (en) Oral pharmaceutical composition of Tecovirimat and preparation method thereof
CN102871950B (zh) 一种熊果酸固体分散体及其制备方法
Sobh et al. Formulation and in vitro characterization of anticancer drugs encapsulated chitosan/multi-walled carbon nanotube nanocomposites
Wei et al. Solidification of hesperidin nanosuspension by spray drying optimized by design of experiment (DoE)
Tierney et al. Carrier particle design for stabilization and isolation of drug nanoparticles
Barrett et al. Increasing the dissolution rate of itraconazole processed by gas antisolvent techniques using polyethylene glycol as a carrier
Nep et al. Evaluation of Grewia polysaccharide gum as a suspending agent
Liu et al. Preparation nanocrystals of poorly soluble plant compounds using an ultra-small-scale approach
Makarem et al. Electro-organic synthesis of nanosized particles of 2-amino-pyranes
CN105688223B (zh) 一种小粒径微晶纤维素丸芯的制备工艺
CN103917485B (zh) 纳米颗粒制备方法
Bhargavi et al. Generation of Hollow crystals of a drug with lamellar structure forming ability
JPH107558A (ja) 溶解性改善製剤
Bodnár et al. Drug loading and dissolution properties of dalcetrapib–montmorillonite nanocomposite microparticles
Crowley et al. Drug-fatty acid salt with wax-like properties employed as binder in melt granulation
KR101021619B1 (ko) 안정성이 증진된 알파-리포익산의 나노입자 제제 및 그제조방법
Tyagi et al. formulation and evaluation of Zidovudine nanosuspensions using a novel bio polymer from the seeds of Buchanania Lanzan